CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 147 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2023. The put-call ratio across all filers is 0.86 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $63,099,260 | -31.8% | 2,292,851 | -15.9% | 0.00% | -40.0% |
| Q2 2023 | $92,537,493 | +11.7% | 2,727,306 | +18.4% | 0.01% | 0.0% |
| Q1 2023 | $82,844,558 | -59.4% | 2,302,525 | -49.8% | 0.01% | -16.7% |
| Q4 2022 | $204,260,210 | +129.1% | 4,582,908 | +44.5% | 0.01% | 0.0% |
| Q3 2022 | $89,153,000 | +2.4% | 3,171,578 | -1.8% | 0.01% | +20.0% |
| Q2 2022 | $87,050,000 | -4.7% | 3,228,852 | +20.4% | 0.01% | 0.0% |
| Q1 2022 | $91,374,000 | -0.1% | 2,682,728 | +13.3% | 0.01% | +25.0% |
| Q4 2021 | $91,501,000 | -8.7% | 2,368,040 | +27.5% | 0.00% | -20.0% |
| Q3 2021 | $100,266,000 | +43.2% | 1,857,118 | -11.3% | 0.01% | +25.0% |
| Q2 2021 | $70,031,000 | +81.1% | 2,094,218 | +11.6% | 0.00% | +100.0% |
| Q1 2021 | $38,666,000 | +21.9% | 1,876,977 | +3.7% | 0.00% | 0.0% |
| Q4 2020 | $31,716,000 | +8335.1% | 1,810,260 | +7030.7% | 0.00% | – |
| Q3 2020 | $376,000 | – | 25,387 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |